CION Ameerpet
There is no single brain tumour survival number, because "brain tumour" is not one disease. We'll help you understand the honest ranges — by type, grade and molecular markers — and what they mean for your family.
If you or someone you love has just been diagnosed, you are searching for one number: how long? You deserve an honest answer, and the honest answer is that there is no single brain tumour survival rate. "Brain tumour" is not one disease — it is dozens of different tumours, from slow-growing benign growths to aggressive cancers, and each has its own outlook. What the published evidence offers is a range and a set of averages, not a prediction for any one person.
The difference is enormous. Many benign tumours — such as most meningiomas — are associated with a long, near-normal life expectancy after treatment. At the other end, glioblastoma (GBM, WHO Grade 4) has a median overall survival of about 15 to 18 months with full standard treatment. Between these sit low-grade gliomas, Grade 3 tumours, and brain metastases, each with very different numbers. "Median" simply means the midpoint: half of patients live longer, half shorter. It is a statistic about thousands of people, not a countdown for your loved one.
This page explains survival across the main brain tumour types, how WHO grade and molecular markers shape the outlook, and what care is available. To go deeper on grade, see how tumour grade affects prognosis, or start with the brain cancer & tumour hub.
Most primary brain tumours are described by WHO grade (1 to 4), not by the Stage I–IV system used for other cancers — because they rarely spread outside the brain. The 2021 WHO classification now defines many tumours partly by molecular markers such as IDH status, which is why two tumours of the same grade can have very different outlooks. Both NCCN and EANO guidelines stress that survival figures are group averages, and an individual's prognosis depends on tumour type, grade, age, fitness, the amount of tumour safely removed, and molecular results.
Before any survival figure makes sense, one distinction matters most: whether the tumour is benign (non-cancerous) or malignant (cancerous). It changes the outlook completely.
Non-cancerous tumours such as most meningiomas, pituitary adenomas and acoustic neuromas grow slowly and rarely spread. Many are associated with a near-normal life expectancy after surgery or monitoring. "Benign" describes the cells, not the location — see the outlook for benign brain tumours.
Cancerous tumours such as high-grade gliomas and glioblastoma grow faster and are harder to treat, so survival is measured differently. Even here the range is wide, and molecular markers like IDH and MGMT can meaningfully improve the outlook. Grade and biology matter as much as the word "cancer".
A median or a 5-year percentage cannot tell you what will happen to your family member. Older data does not capture newer treatments, individual markers, or how well a person responds. Use statistics to understand the landscape and ask better questions — never as a deadline. Speak to our team.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you need the survival figures explained gently, a diagnosis confirmed, or a free second opinion — CION's neuro-oncology team is here. We make decisions for healing, not billing.
Because "brain tumour" covers many different diseases, survival varies enormously between them. Below are the main types, with outlook and survival ranges drawn from published data and from NCCN and EANO guidance. Every figure is a group average — your neuro-oncologist will explain what it means for your specific tumour and molecular results.
Most meningiomas are benign (WHO Grade 1), slow-growing, and associated with an excellent long-term outlook — often a near-normal life expectancy after complete surgical removal, and many small ones can simply be monitored. A minority are atypical (Grade 2) or malignant (Grade 3) and need closer treatment and follow-up. Surgery, when needed, is coordinated with accredited neurosurgical partners, while CION delivers radiation, monitoring imaging and supportive care directly. For more, read the outlook for benign brain tumours.
Low-grade gliomas grow slowly, and many patients live for many years — sometimes decades — particularly younger adults and those whose tumour can be largely removed. Grade 1 tumours (such as pilocytic astrocytoma) are often curable with surgery alone. Grade 2 tumours grow slowly but can recur or transform over time, so long-term follow-up matters. IDH-mutant low-grade gliomas carry a notably more favourable outlook, which is why molecular testing is so important at diagnosis.
Grade 3 (high-grade) gliomas are aggressive but generally carry a better outlook than glioblastoma, and survival can be measured in several years rather than months for many patients. Molecular markers matter enormously here: IDH-mutant tumours, and oligodendrogliomas with combined 1p/19q co-deletion, tend to respond well to radiation and chemotherapy and have a notably more favourable prognosis. This is why accurate molecular testing is essential — grade alone no longer tells the full story.
Glioblastoma is the most common and most aggressive primary brain cancer in adults. With the full standard sequence — maximal safe surgery, radiation given together with alkylating chemotherapy, then further chemotherapy — published studies report a median overall survival of about 15 to 18 months, with roughly 5% to 10% of patients alive at 5 years. Tumours with a methylated MGMT gene tend to do meaningfully better. For a fuller, gentle explanation of the most aggressive end of the range, see our guide to the prognosis for advanced or aggressive brain tumours.
Brain metastases are more common than all primary brain tumours combined, and the outlook depends mainly on the primary cancer and how well it is controlled, not on the brain lesions alone. Modern stereotactic radiosurgery can treat several lesions precisely while protecting cognition, and newer systemic treatments mean some patients live well for a long time. Cross-link to the relevant primary cancer hub for context: lung cancer, breast cancer, melanoma & skin cancer, or kidney cancer.
Acoustic neuromas (vestibular schwannomas) and most pituitary adenomas are benign and rarely life-threatening. They are associated with a very good long-term outlook, and many small ones are simply monitored with regular scans. Treatment, when needed, focuses on protecting hearing, vision, balance and hormone function — using radiosurgery, medical therapy or surgery coordinated with accredited neurosurgical partners. The main concern is usually symptom control and quality of life rather than survival.
Brain tumours in children — such as medulloblastoma, pilocytic astrocytoma and certain gliomas — behave very differently from adult tumours and are managed under specialist paediatric protocols. Some childhood types have a very good outlook and high survival with modern treatment. If the patient is a child, the right home for survival information and care is our paediatric cancer hub, where treatment is tailored to a child's growing brain and family needs. Please use that hub rather than this adult-focused page for a child's outlook.
All figures above are published ranges and group averages drawn from NCCN and EANO guidance and clinical-trial data. They describe populations, not individuals, and should never be read as guarantees.
Most primary brain tumours are given a WHO grade from 1 to 4, based on how the cells look and behave under the microscope. Broadly, the lower the grade, the slower the growth and the better the average outlook — though molecular markers now refine this picture. For a deeper look, see how tumour grade affects prognosis.
Because grade and biology interact, the most accurate outlook comes from reviewing them together. Speak to a CION specialist to have your own results explained in plain language.
Since the 2021 WHO classification, brain tumours are defined partly by their molecular profile — not grade alone. An IDH-mutant glioma generally has a more favourable outlook than an IDH wild-type tumour of the same grade, and MGMT promoter methylation predicts a better response to alkylating chemotherapy. According to NCCN and EANO, this is why two tumours that look identical under the microscope can carry very different survival ranges once the molecular results are known. CION arranges these tests as standard on malignant glioma samples.
Whatever the tumour type, the same handful of factors most strongly influence survival. Your neuro-oncologist weighs them together — no single factor decides the outcome on its own.
A brain tumour diagnosis affects the whole family. CION's role is to give you clarity, the best possible treatment, and steady support throughout. Here is what our team delivers directly:
A gentle note on the goal: for many benign and low-grade tumours the outlook is excellent, and some are curable. For aggressive tumours a cure may not be realistic — and we will never promise one. What good care can do is control the tumour, extend meaningful time, and protect quality of life. Talk to a CION specialist about a realistic, personalised plan, or explore brain tumour treatment in Hyderabad. You can also call us on 18002028726 to talk today.
A free written second opinion from CION's neuro-oncology tumour board — so you understand the survival outlook clearly and know every option available to your family.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.There is no single brain tumour survival rate, because "brain tumour" covers dozens of very different diseases. Many benign tumours — such as most meningiomas — are associated with long, near-normal life expectancy after treatment. High-grade tumours are very different: for glioblastoma (WHO Grade 4), published studies report a median overall survival of about 15 to 18 months with full standard treatment. Grade 1 and 2 tumours, and tumours with favourable molecular markers, do far better. NCCN and EANO guidance always frame survival as ranges and group averages, never a prediction for one person. The most accurate picture comes from your own neuro-oncologist after reviewing the MRI, pathology and molecular results together.
Grade is one of the strongest drivers of prognosis. Most primary brain tumours are given a WHO grade from 1 to 4 based on how the cells look and behave under the microscope. Grade 1 tumours grow slowly and are often curable with surgery alone; Grade 2 tumours grow slowly but can return; Grade 3 tumours are faster-growing but frequently respond well to treatment; Grade 4 tumours such as glioblastoma are the most aggressive. But grade is no longer the whole story — molecular markers now matter just as much. Read more about how tumour grade affects prognosis.
For most benign (non-cancerous) brain tumours, life expectancy is often close to normal, especially when the tumour can be fully removed or safely monitored. Meningiomas, most pituitary adenomas, acoustic neuromas and many low-grade tumours fall into this group. That said, "benign" describes the cells, not the location — a benign tumour pressing on a critical area can still cause serious problems and needs proper treatment. The outlook depends on the tumour type, its size and position, and whether it can be removed. Learn more about the outlook for benign brain tumours.
According to NCCN and EANO, the strongest factors are: the exact tumour type and WHO grade; molecular markers such as IDH status, MGMT methylation and 1p/19q co-deletion; the patient's age; their performance status (how active and independent they are); and how much tumour could be safely removed. For brain metastases, the type and control of the primary cancer matter most. Your neuro-oncologist weighs all of these together — no single factor decides the outcome, which is why two people with the same diagnosis can have very different journeys.
Yes — significantly. Since the 2021 WHO classification, tumours are defined partly by their molecular profile, not grade alone. IDH-mutant gliomas generally grow more slowly and have a more favourable outlook than IDH wild-type tumours of the same grade. MGMT promoter methylation predicts how well alkylating chemotherapy will work. In oligodendroglioma, combined 1p/19q co-deletion signals a better response to treatment. CION arranges these tests as standard on malignant glioma samples, because two tumours that look identical under the microscope can have very different outlooks once the molecular results are known.
Survival statistics describe large groups of patients studied in the past — they cannot predict what will happen to one person. They do not capture newer treatment combinations, an individual's molecular markers, or how well someone responds. Please use them to understand the general landscape and to ask better questions, not as a countdown. Some patients live well beyond the average for years. The most accurate, individual picture comes from your own neuro-oncologist after reviewing the imaging, pathology and molecular results together — which is exactly what CION's tumour board provides.
CION delivers directly: radiation therapy (IMRT/IGRT) and coordinated radiosurgery, systemic therapy including alkylating chemotherapy and treatment for brain metastases, imaging and molecular testing, steroid and seizure management, and supportive and rehabilitation care. All neurosurgery — biopsy or resection — is coordinated with accredited neurosurgical partners. Every case is reviewed by a multidisciplinary tumour board, with a 45-minute consultation and a free written second opinion. Explore brain tumour treatment in Hyderabad.
Disclaimer: This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Survival figures are published ranges and group averages — they describe populations, not individuals, and are not predictions or guarantees for any one patient. Always consult a qualified oncologist for guidance specific to your medical condition. This page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines, including NCCN and EANO.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.